comprehensive -WSS

comprehensive

author：fashion 2025-09-30 00:09:45 - browse：9636

U.S. legislation that would sever ties with Chinese drugmakers would jeopardize the drug supply for millions of American patients if it’s passed, the biotechnology industry’s main trade group has told Congress.

Congress is considering legislation, called the BIOSECURE Act, that would make it difficult for Chinese contract development and manufacturing organizations to do business with biotechnology companies that work with the U.S. federal government. Biotechs hire Chinese CDMOs, as they’re often called, for services that include product manufacturing, development, formulation, packaging, and distribution.

The BIOSECURE Act would stop the federal government from contracting with, or providing grants to, companies that do business with so-called Chinese “companies of concern.” The impact of the legislation would depend in large part on who is in the White House. The White House’s Office of Management and Budget would determine which companies are blacklisted, but a handful of specific companies would automatically go on that list, including the biotech giant WuXi AppTec.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Roche’s Alnylam deal shows drug firms interested in heart drugs

focus

WSS

No plane should take off without an EpiPen onboard

How doctors’ personal politics affect patients

Dems pitch expanding Medicare power to negotiate drug prices

STAT Report: Patient voices and perspectives

Dems pitch expanding Medicare power to negotiate drug prices

'Investigate these claims': UFO transparency at center of House hearing

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Wikipedia

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

EQRx, failed developer of low

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

CDC Director Mandy Cohen on transparency, trust, and health

Wildfire smoke exposes gaps in outdoor worker protections

Wildfire pollution widens asthma inequities on Long Island

Affirmative action in medical school literally saved lives

Sage hopes for a blockbuster in antidepressant now before FDA

Continuity nursing helped my family in our darkest PICU moments

New lawsuit accuses health insurer Cigna of denying claims in bulk

focus

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

The battle over 'scope creep' and who gets to be called 'doctor'

What the airline industry can learn from medicine

Mitch McConnell episode has important public health takeaway

Vertex non

Biogen says it will cut costs by $700 million, slash 1,000 jobs

focus

leisure time

focus

focus